当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine.

Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine.

Abstract：

:A varicella-zoster virus (VZV) seropositive individual was immunized with 100 micrograms of purified VZV TgpI-511 glycoprotein subunit antigen formulated with monophosphoryl lipid A. Serum samples were obtained during a 40-day period post-immunization (PI) and analysed by immunoprecipitation and virus neutralization tests. The results from immunoprecipitation studies revealed an increase in VZV anti-gpI antibody titer as early as 6 days PI which continued to rise during 40 days PI. In addition, virus neutralization tests showed a 21.0% VZV neutralization 6 days PI with an increase to a 96.7% VZV neutralization 40 days PI. These results suggested that the candidate VZV glycoprotein subunit vaccine (TgpI-511) was capable of boosting the production of neutralizing antibodies in the immunized VZV seropositive human subject.

journal_name

Vaccine

journal_title

Vaccine

authors

Vafai A

doi

10.1016/0264-410x(94)00073-v

subject

Has Abstract

pub_date

1995-10-01 00:00:00

pages

1336-8

issue

14

eissn

0264-410X

issn

1873-2518

pii

0264410X9400073V

journal_volume

13

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Development of a vaccine-challenge model for avian metapneumovirus subtype C in turkeys.

    abstract：:The objective of this study was to evaluate different preparations of avian metapneumovirus (aMPV) subtype C as vaccine challenge in turkeys. Two aMPV isolates and their respective nasal turbinate homogenates after propagation in turkeys were used in the study. Significantly higher clinical sign scores were recorded i...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.10.037

    authors： Velayudhan BT,Noll SL,Thachil AJ,Shaw DP,Goyal SM,Halvorson DA,Nagaraja KV

    更新日期：2007-02-26 00:00:00

  • Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity.

    abstract：:CIMAvax-EGF consists of a human recombinant epidermal growth factor (EGF), coupled to P64k, a recombinant carrier protein from N. meningitis, and Montanide ISA 51 as adjuvant. The vaccine immunization induces a specific antibody production, inhibiting the EGF/EGF-R interaction through EGF deprivation. The objective of...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.01.092

    authors： Mancebo A,Casacó A,González B,Ledón N,Sorlozabal J,León A,Gómez D,González Y,Bada AM,González C,Arteaga ME,Ramírez H,Fuentes D

    更新日期：2012-05-09 00:00:00

  • Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.

    abstract：INTRODUCTION:Live-attenuated influenza vaccines (LAIVs) have the potential to be affordable, effective, and logistically feasible for immunization of children in low-resource settings. MATERIAL AND METHODS:We conducted a phase II, randomized, double-blind, parallel group, placebo-controlled trial on the safety of the ...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2015.04.048

    authors： Ortiz JR,Goswami D,Lewis KD,Sharmeen AT,Ahmed M,Rahman M,Rahman MZ,Feser J,Neuzil KM,Brooks WA

    更新日期：2015-06-26 00:00:00

  • Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope.

    abstract：:The severe acute respiratory syndrome coronavirus nucleocapsid protein (SARS-CoV N) is one of the major targets for SARS vaccine due to its high potency in triggering immune responses. In this study, we have identified a novel HLA-A*0201 restricted epitope, N220 (LALLLLDRL), of the SARS-CoV N-protein through bioinform...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.05.025

    authors： Cheung YK,Cheng SC,Sin FW,Chan KT,Xie Y

    更新日期：2007-08-10 00:00:00

  • Amount of maternal rotavirus-specific antibodies influence the outcome of rotavirus vaccination of newborn mice with virus-like particles.

    abstract：:In presence of low or high levels of rotavirus-specific maternal antibodies, the ability of newborn mice to respond to immunization with rotavirus RF 8*-2/6/7 VLPs, was evaluated. After parenteral vaccination, 100% of offspring born to low-antibody-titer dams developed rotavirus-specific IgG antibodies (n=7). In contr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.11.089

    authors： Johansson E,Istrate C,Charpilienne A,Cohen J,Hinkula J,Poncet D,Svensson L,Johansen K

    更新日期：2008-02-06 00:00:00

  • Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.

    abstract：:The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formul...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.06.017

    authors： Hu MC,Jones T,Kenney RT,Barnard DL,Burt DS,Lowell GH

    更新日期：2007-08-21 00:00:00

  • Prevention of meningococcal disease at mass gatherings: Lessons from the Hajj and Umrah.

    abstract：:Meningococcal disease is a serious public health threat given the seriousness of the illness, its disabling sequelae and its potential for epidemic spread. The disease is a concern during mass gatherings which provide conditions that facilitate transmission of infectious agents including Neisseria meningitidis. Implem...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2018.06.030

    authors： Yezli S,Gautret P,Assiri AM,Gessner BD,Alotaibi B

    更新日期：2018-07-25 00:00:00

  • The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales.

    abstract：:A cost-effectiveness analysis of the introduction of acellular pertussis booster doses at either 4 or 15 years of age was performed. A transmission dynamic model was used to predict the level of indirect protection in those too young to be vaccinated. Multivariate sensitivity analyses were performed. In England and Wa...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00473-x

    authors： Edmunds WJ,Brisson M,Melegaro A,Gay NJ

    更新日期：2002-01-31 00:00:00

  • Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.

    abstract：:Human papillomavirus type 16 (HPV16)-transformed mouse TC-1 cells are extensively used in the evaluation of efficacy of experimental vaccines against tumours induced by HPVs. As these cells strongly express MHC class I molecules and downregulation of MHC class I surface expression is one of the important mechanisms th...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(02)00519-4

    authors： Smahel M,Síma P,Ludvíková V,Marinov I,Pokorná D,Vonka V

    更新日期：2003-03-07 00:00:00

  • Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.

    abstract：:We report the rationale, design, methods and details of participation of a community-based, double-blind, randomized clinical trial of an HPV 16 and 18 vaccine conducted in two provinces of Costa Rica to investigate the efficacy and population impact of the vaccine in the prevention of cervical cancer precursors. More...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2008.07.002

    authors： Herrero R,Hildesheim A,Rodríguez AC,Wacholder S,Bratti C,Solomon D,González P,Porras C,Jiménez S,Guillen D,Morales J,Alfaro M,Cyr J,Morrisey K,Estrada Y,Cortés B,Morera LA,Freer E,Schussler J,Schiller J,Lowy D,S

    更新日期：2008-09-02 00:00:00

  • Effect of zinc and vitamin A supplementation on antibody responses to a pneumococcal conjugate vaccine in HIV-positive injection drug users: a randomized trial.

    abstract：:HIV-infected individuals have impaired immune responses to vaccines and high rates of pneumococcal disease. The effect of vitamin A and zinc supplementation on the immunogenicity of a 7-valent pneumococcal CRM-197 conjugate vaccine (PC-7) was evaluated in 118 HIV+ injection drug users. Subjects were randomized to oral...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2005.09.047

    authors： Deloria-Knoll M,Steinhoff M,Semba RD,Nelson K,Vlahov D,Meinert CL

    更新日期：2006-03-06 00:00:00

  • Acceptability of intranasal live attenuated influenza vaccine, influenza knowledge and vaccine intent in The Gambia.

    abstract：BACKGROUND:The burden of influenza is increasingly recognised in Africa. The WHO recommends introducing influenza vaccination to high-risk groups: pregnant women, children <5 years, and the elderly. The Gambia currently has no influenza vaccination policy, but the NASIMMUNE study, a clinical trial of intranasal live at...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.02.037

    authors： Armitage EP,Camara J,Bah S,Forster AS,Clarke E,Kampmann B,de Silva TI

    更新日期：2018-03-20 00:00:00

  • Introducing cholera vaccination in Asia, Africa and Haiti: a meeting report.

    abstract：:Orally-administered cholera vaccine (OCV) has been increasingly examined as an additional tool to intervene against endemic and epidemic cholera. In 2013, short- and long-term field experience with OCV under nine distinctive field settings was reported from India, Bangladesh, Vietnam, Guinea, Haiti, and Thailand. Lead...

    journal_title：Vaccine

    pub_type：

    doi：10.1016/j.vaccine.2014.11.031

    authors： Hall RH,Sack DA

    更新日期：2015-01-15 00:00:00

  • The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity.

    abstract：:We recently developed a novel immunomodulating gene fusion protein, CTA1-DD, that combines the ADP-ribosylating ability of cholera toxin (CT) with a dimer of an Ig-binding fragment, D, of Staphylococcus aureus protein A. The CTA1-DD adjuvant was found to be non-toxic and greatly augmented T cell dependent and independ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(00)00487-4

    authors： Lycke N,Schön K

    更新日期：2001-03-21 00:00:00

  • Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.

    abstract：:Though widely used, the BCG vaccine has had little apparent effect on rates of adult pulmonary tuberculosis. Moreover, the risk of disseminated BCG disease in immunocompromised individuals means that improved TB vaccines ideally need to be able to efficiently prime mycobacterially-naïve individuals as well as boost in...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2010.02.094

    authors： van Dissel JT,Arend SM,Prins C,Bang P,Tingskov PN,Lingnau K,Nouta J,Klein MR,Rosenkrands I,Ottenhoff TH,Kromann I,Doherty TM,Andersen P

    更新日期：2010-04-30 00:00:00

  • Efficacy of a novel inactivated Lawsonia intracellularis vaccine in pigs against experimental infection and under field conditions.

    abstract：:The efficacy of a novel inactivated Lawsonia intracellularis vaccine, Porcilis® Lawsonia, was compared to that of a commercially available live attenuated vaccine in three experimental vaccination-challenge studies in pigs. The efficacy of the new vaccine was further tested under field conditions on a farm with a hist...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.02.067

    authors： Jacobs AAC,Harks F,Hazenberg L,Hoeijmakers MJH,Nell T,Pel S,Segers RPAM

    更新日期：2019-04-03 00:00:00

  • Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants.

    abstract：:A prospective, randomised, controlled observer-blind trial measuring the efficacy and immunogenicity of trivalent influenza vaccine (TIV) and the immunogenicity of quadrivalent meningococcal conjugate vaccine (MCV) in pregnant women and their infants up to 6 months of age was conducted in Mali. Here we reported the im...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2019.03.045

    authors： Findlow H,Tapia MD,Sow SO,Haidara FC,Coulibaly F,Keita AM,Diallo F,Doumbia M,Traore A,Schluterman N,Clark DA,Borrow R,Levine MM

    更新日期：2019-04-24 00:00:00

  • Killed Bacillus subtilis spores as a mucosal adjuvant for an H5N1 vaccine.

    abstract：:Heat killed spores of the Gram-positive bacterium Bacillus subtilis have been evaluated as a vaccine delivery system with mucosal adjuvant properties for influenza. Killed spores were able to bind H5N1 virions (NIBRG-14; clade 1) and, when intra-nasally administered to mice, resulting immune responses, both humoral an...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.03.016

    authors： Song M,Hong HA,Huang JM,Colenutt C,Khang DD,Nguyen TV,Park SM,Shim BS,Song HH,Cheon IS,Jang JE,Choi JA,Choi YK,Stadler K,Cutting SM

    更新日期：2012-05-09 00:00:00

  • Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant.

    abstract：:This work describes the formulation design and development of a novel protein based adjuvant, a double mutant of heat labile toxin (dmLT), based on knowledge of the protein's structural integrity and physicochemical degradation pathways. Various classes of pharmaceutical excipients were screened for their stabilizing ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.03.101

    authors： Toprani VM,Sahni N,Hickey JM,Robertson GA,Middaugh CR,Joshi SB,Volkin DB

    更新日期：2017-10-04 00:00:00

  • Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant.

    abstract：:Intranasal (i.n.) vaccination with two suboptimal doses of 8 microg of deglycosylated chain A ricin (DGCA) stimulated low anti-ricin ELISA IgG and neutralizing antibody responses and the vaccine was only marginally protective against a lethal ricin toxin aerosol challenge. However, in the presence of 4, 2, or 1 microg...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.12.034

    authors： Kende M,Del Giudice G,Rivera N,Hewetson J

    更新日期：2006-03-15 00:00:00

  • Opportunities and challenges of Web 2.0 for vaccination decisions.

    abstract：:A growing number of people use the Internet to obtain health information, including information about vaccines. Websites that allow and promote interaction among users are an increasingly popular source of health information. Users of such so-called Web 2.0 applications (e.g. social media), while still in the minority...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.02.025

    authors： Betsch C,Brewer NT,Brocard P,Davies P,Gaissmaier W,Haase N,Leask J,Renkewitz F,Renner B,Reyna VF,Rossmann C,Sachse K,Schachinger A,Siegrist M,Stryk M

    更新日期：2012-05-28 00:00:00

  • Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim.

    abstract：BACKGROUND AND OBJECTIVES:India has the highest under-five death toll globally, approximately 20% of which is attributed to vaccine-preventable diseases. India's Universal Immunization Programme (UIP) is working both to increase immunization coverage and to introduce new vaccines. Here, we analyze the disease and finan...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.04.080

    authors： Megiddo I,Colson AR,Nandi A,Chatterjee S,Prinja S,Khera A,Laxminarayan R

    更新日期：2014-08-11 00:00:00

  • Protection against infectious bronchitis virus by spike ectodomain subunit vaccine.

    abstract：:The avian coronavirus infectious bronchitis virus (IBV) S1 subunit of the spike (S) glycoprotein mediates viral attachment to host cells and the S2 subunit is responsible for membrane fusion. Using IBV Arkansas-type (Ark) S protein histochemistry, we show that extension of S1 with the S2 ectodomain improves binding to...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.09.013

    authors： Eldemery F,Joiner KS,Toro H,van Santen VL

    更新日期：2017-10-13 00:00:00

  • Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA.

    abstract：:Particle-mediated (gene gun) DNA transfer to the epidermis was evaluated for its ability to elicit humoral and cytotoxic T lymphocyte responses using decreasing quantities of plasmid DNA-based antigen expression vectors. Using plasmids encoding human growth hormone, human alpha-1-antitrypsin, and influenza virus nucle...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(95)00069-d

    authors： Pertmer TM,Eisenbraun MD,McCabe D,Prayaga SK,Fuller DH,Haynes JR

    更新日期：1995-01-01 00:00:00

  • Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin.

    abstract：:The efficacy of a licensed human anthrax vaccine (Anthrax Vaccine Adsorbed (AVA)) was tested in guinea pigs, rabbits, and rhesus macaques against spore challenge by Bacillus anthracis isolates of diverse geographical origin. Initially, groups of Hartley guinea pigs were vaccinated at 0 and 4 weeks with AVA, then chall...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00021-4

    authors： Fellows PF,Linscott MK,Ivins BE,Pitt ML,Rossi CA,Gibbs PH,Friedlander AM

    更新日期：2001-04-30 00:00:00

  • Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature.

    abstract：:A systematic review was performed to assess the safety and immunogenicity of the prepandemic H5N1 influenza vaccines licensed so far. A bibliographic search according to the COSI protocol was carried out and 8 of 235 potentially relevant publications were selected. Quality assessment was defined with both CASP and Jad...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2010.03.068

    authors： Prieto-Lara E,Llanos-Méndez A

    更新日期：2010-06-11 00:00:00

  • Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults.

    abstract：:Human papillomavirus (HPV) infection is highly prevalent and can lead to cancer; the development of safe and efficacious vaccines for HPV is a major public health concern. The two licensed HPV vaccines contain recombinant virus-like particles of HPV 16 and 18; one of such vaccines also protects against HPV types 6 and...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.08.011

    authors： Giacomet V,Penagini F,Trabattoni D,Viganò A,Rainone V,Bernazzani G,Bonardi CM,Clerici M,Bedogni G,Zuccotti GV

    更新日期：2014-09-29 00:00:00

  • Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project.

    abstract：BACKGROUND:The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines using European healthcare databases. Event misclassification can result in biased estimates. Using di...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.07.045

    authors： Gini R,Dodd CN,Bollaerts K,Bartolini C,Roberto G,Huerta-Alvarez C,Martín-Merino E,Duarte-Salles T,Picelli G,Tramontan L,Danieli G,Correa A,McGee C,Becker BFH,Switzer C,Gandhi-Banga S,Bauwens J,van der Maas NAT,Spiteri

    更新日期：2020-12-22 00:00:00

  • Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study.

    abstract：BACKGROUND:The demand on effective and safe anthrax vaccine is increasing as a part of the preparedness for possible bioterrorism in the future. We performed a randomized, single-blind, placebo controlled phase II clinical study to evaluate the immunogenicity and safety of a novel recombinant protective antigen (rPA) a...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2019.05.057

    authors： Kang CK,Kim NH,Kim CJ,Rhie GE,Jo SK,Ahn M,Kang J,Choe PG,Park WB,Kim NJ,Oh MD

    更新日期：2019-06-27 00:00:00

  • Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users.

    abstract：:Fifty injecting drug users (IDUs) were recruited to evaluate the efficacy of an hepatitis B virus (HBV) vaccination campaign to be carried out in a Public centre for Drug Users (PCDU). The vaccination schedule was successfully performed in most patients, who showed a great interest in this problem. After three doses o...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(96)00290-3

    authors： Lugoboni F,Migliozzi S,Schiesari F,Pauletto N,Bovo GL,Ciaffoni S,Mezzelani P

    更新日期：1997-06-01 00:00:00